Victor Wembanyama does it all on the basketball court. On Tuesday he put his scoring hat on. The San Antonio Spurs superstar scored 25 points against the Los Angeles Lakers — in the first eight ...

Chelsea didn’t make any new first team signings in January, but they did add one new player – Mamadou Sarr was recalled from his loan at Strasbourg. He’s yet to play a minute since moving, and in his ...

Check out the first 28 minutes of Mewgenics! The latest from Edmund McMillen (The Binding of Isaac) and Tyler Glaiel (The End is Night), Mewgenics is a tactical roguelite with home management elements ...

Check out the first 28 minutes of Mewgenics! The latest from Edmund McMillen (The Binding of Isaac) and Tyler Glaiel (The End is Night), Mewgenics is a tactical roguelite with home management elements ...

The James Harden era of the Cleveland Cavaliers began with a close win over one of the worst teams in the NBA on Saturday. The Cavaliers came back to beat the Sacramento Kings, in Harden's debut with ...

The Bulls were looking very good in the talent portion of their Mr. Chicago Bulls pageant Saturday night, at least into the fourth quarter with a 103-97 lead over the Denver Nuggets and all-everything ...

Welcome to The Daily’s photo blog: Captured. This is a space for The Daily’s photographers to share their best work, including photos from weekend performances and events around the community. You can ...

Many meetings fall short not because of poor preparation or lack of expertise, but because of the conditions under which decisions are made. People arrive with clear goals and strong credentials, yet ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma ...

So much for having a mistake-free Olympics. The 2026 Winter Olympics are officially underway. Well, sort of. If you’re hoping for this year’s Winter Olympics to go off without a hitch, that’s already ...

The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, ...